Page 202 - Strategies for non-invasive managementof high-grade cervical intraepithelial neoplasia - prognostic biomarkers and immunotherapy Margot Maria Koeneman

Chapter 10
30. Bansal A, Pepe MS. When does combining markers improve classification performance and what are implications for practice? Stat Med. 2013;32(11):1877-92.
31. Tainio K, Athanasiou A, Tikkinen KAO, Aaltonen R, Cardenas J, Hernandes, et al. Clinical course of untreated cervical intraepithelial neoplasia grade 2 under active surveillance: systematic review and meta-analysis. BMJ. 2018;360:k499.
32. Massad LS, Einstein MH, Huh WK, Katki HA, Kinney WK, Schiffman M, et al. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis. 2013;17(5 Suppl 1):S1-S27.
33. Ismail SM, Colclough AB, Dinnen JS, Eakins D, Evans DM, Gradwell E, et al. Observer variation in histopathological diagnosis and grading of cervical intraepithelial neoplasia. BMJ. 1989;298(6675):707-10.
34. Carreon JD, Sherman ME, Guillen D, Solomon D, Herrero R, Jeronimo J, et al. CIN2 is a much less reproducible and less valid diagnosis than CIN3: results from a histological review of population-based cervical samples. Int J Gynecol Pathol. 2007;26(4):441-6.
35. Dalla Palma P, Giorgi Rossi P, Collina G, Buccoliero AM, Ghiringhello B, Gilioli E, et al. The reproducibility of CIN diagnoses among different pathologists: data from histology reviews from a multicenter randomized study. Am J Clin Pathol. 2009;132(1):125-32.
36. Cai B, Ronnett BM, Stoler M, Ferenczy A, Kurman RJ, Sadow D, et al. Longitudinal evaluation of interobserver and intraobserver agreement of cervical intraepithelial neoplasia diagnosis among an experienced panel of gynecologic pathologists. Am J Surg Pathol. 2007;31(12):1854- 60.
37. Steenbergen RD, Snijders PJ, Heideman DA, Meijer CJ. Clinical implications of (epi)genetic changes in HPV-induced cervical precancerous lesions. Nat Rev Cancer. 2014;14(6):395-405.
38. Uleberg KE, Munk AC, Brede C, Gudlaugsson E, van Diermen B, Skaland I, et al. Discrimination of grade 2 and 3 cervical intraepithelial neoplasia by means of analysis of water soluble proteins recovered from cervical biopsies. Proteome Sci. 2011;9:36.
39. Fonseca-Moutinho JA. Smoking and cervical cancer. ISRN Obstet Gynecol. 2011;2011:847684.
40. Loopik DL, Doucette S, Bekkers RL, Bentley JR. Regression and Progression Predictors of CIN2
in Women Younger Than 25 Years. J Low Genit Tract Dis. 2016;20(3):213-7.
41. Miyamoto S, Hasegawa J, Morioka M, Hirota Y, Kushima M, Sekizawa A. The association between p16 and Ki67 immunohistostaining and the progression of cervical intraepithelial
neoplasia grade 2. Int J Gynaecol Obstet. 2016;134(1):45-8.
42. Guillaud M, Buys TP, Carraro A, Korbelik J, Follen M, Scheurer M, et al. Evaluation of HPV
infection and smoking status impacts on cell proliferation in epithelial layers of cervical
neoplasia. PLoS One. 2014;9(9):e107088.
43. Samir R, Asplund A, Tot T, Pekar G, Hellberg D. Tissue tumor marker expression in smokers,
including serum cotinine concentrations, in women with cervical intraepithelial neoplasia
or normal squamous cervical epithelium. Am J Obstet Gynecol. 2010;202(6):579 e1-7.
44. Munoz N, Franceschi S, Bosetti C, Moreno V, Herrero R, Smith JS, et al. Role of parity and human papillomavirus in cervical cancer: the IARC multicentric case-control study. Lancet.
2002;359(9312):1093-101.
200